Form 8-K - Current report:
SEC Accession No. 0001193125-25-040920
Filing Date
2025-02-28
Accepted
2025-02-28 08:30:54
Documents
14
Period of Report
2025-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d889916d8k.htm   iXBRL 8-K 25902
2 EX-99.1 d889916dex991.htm EX-99.1 63577
  Complete submission text file 0001193125-25-040920.txt   221637

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20250228.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20250228_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20250228_pre.xml EX-101.PRE 11261
16 EXTRACTED XBRL INSTANCE DOCUMENT d889916d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 25682885
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)